Crossject wins $4.7M more from BARDA to expand ZEPIZURE for children
What's the deal? French specialty pharma firm CrossjectDealroom has a profile for this one. Try Dealroom → has secured an additional $4.7 million in non-dilutive funding from the Biomedical Advanced Research and Development Authority (BARDA). The grant extends its contract to June 21, 2030, and funds an FDA-aligned pediatric development plan for ZEPIZURE, its needle-free midazolam auto-injector.
What's the endgame? The money covers an extra validation campaign and prolonged stability studies to support a future New Drug Application and long-term US stock management. The plan extends ZEPIZURE from adult to pediatric use.
Why now? The Emergency Use Authorization process for the adult indication stays unchanged, with its data package intact. Procurement terms also hold: 306,000 adult and 54,000 pediatric ZENEO auto-injectors worth $60.84 million.
By the numbers: The new grant brings BARDA's total funding for the product to $48 million. Including all options, the contract's total potential value now exceeds $170 million.
Crossject develops needle-free auto-injectors for emergencies. Its ZENEO platform delivers drugs such as midazolam — branded ZEPIZURE — for rapid treatment and emergency preparedness, chiefly in the US. The company carries a market cap of €80.46 million.
The signal: The award ranks among the larger grant rounds raised by French companies, above the 90th percentile all-time. It underscores how government emergency-preparedness budgets, rather than venture capital, are underwriting parts of Europe's specialty pharma pipeline.
Read more: tipranks.com
Image credit: Crossject
